^
    GeneseeqPrime™ analyzes 437 cancer-related genes by next-generation sequencing. It reveals clinically actionable information for therapy selection by providing valuable insight into key oncogenic genes and drug resistance mechanisms. Identifies numerous mutation types: single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), gene fusions and large genomic rearrangements (LGR). Assesses key biomarkers: tumor mutation burden (TMB), microsatellite instability (MSI), DNA mismatch repair (MMR) genes, homologous recombination repair (HRR) genes.
    Cancer:
    Lung Cancer, Solid Tumor
    Gene:
    HRD (Homologous Recombination Deficiency), MSI (Microsatellite instability), TMB (Tumor Mutational Burden)
    Method:
    Next-Generation Sequencing (NGS)
    Approvals
    Date
    Cancer
    Gene
    Drug
    By
    08/22/23
    ST
    -
    CE